Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience

Overview of attention for article published in Breast Cancer Research and Treatment, January 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter: 6 X users

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 43 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 17,742 followers.

RT @nicolobattisti: Our paper on the Palbociclib Compassionate Access Programme experience in heavily pretreated ER+ HER2- #breastcancer pa…

Reply Repost Favourite

RT @nicolobattisti: Our paper on the Palbociclib Compassionate Access Programme experience in heavily pretreated ER+ HER2- #breastcancer pa…

Reply Repost Favourite

RT @nicolobattisti: Our paper on the Palbociclib Compassionate Access Programme experience in heavily pretreated ER+ HER2- #breastcancer pa…

Reply Repost Favourite

RT @nicolobattisti: Our paper on the Palbociclib Compassionate Access Programme experience in heavily pretreated ER+ HER2- #breastcancer pa…

Reply Repost Favourite

RT @nicolobattisti: Our paper on the Palbociclib Compassionate Access Programme experience in heavily pretreated ER+ HER2- #breastcancer pa…

Reply Repost Favourite

Our paper on the Palbociclib Compassionate Access Programme experience in heavily pretreated ER+ HER2- #breastcancer patients treated in 10 Institutions in the UK is available on Breast Cancer Research and Treatment journal @ClinMedJournals #bcsm https://t

Reply Repost Favourite